< Back
Aviation Medication Transparency Act (S. 3258) Advances Out of Markup

Aviation Medication Transparency Act (S. 3258) Advances Out of Markup

July 22, 2026
Today, the Senate Commerce, Science & Transportation Committee took an important step toward improving the FAA's aeromedical certification process by advancing the Aviation Medication Transparency Act (S. 3258) out of markup.
 
SWAPA applauds Senators John Hoeven (R-ND) and Tammy Duckworth (D-IL) for introducing this bipartisan legislation, along with Committee Chairman Ted Cruz (R-TX) and Ranking Member Maria Cantwell (D-WA) for their leadership in moving it forward.
 
For too long, Pilots and air traffic controllers have faced uncertainty when navigating the FAA's medical certification process, particularly when it comes to the use of medications. Clear, transparent guidance empowers aviation professionals to make informed healthcare decisions without unnecessary confusion or delays while maintaining the highest standards of safety.
 
The Aviation Medication Transparency Act would help improve access to timely, understandable information about how medications are evaluated by the FAA, making the aeromedical process more predictable, consistent, and transparent. Better transparency benefits everyone by supporting Pilots and controllers in managing their health while reinforcing a safety-first aviation system.
 
SWAPA remains committed to working with Congress, the FAA, and industry stakeholders to modernize the aeromedical certification process so it better serves the professionals who keep our nation's aviation system safe every day.

Submitting form...